Schildge, S., Bohrer, C., Beck, K
Use has become so popular, in fact, that theyve created shortages, making them unavailable for diabetic patients in need at times
As Shreehas Tambe, Chief Executive Officer and Managing Director of Biocon Biologics Limited, noted regarding demand and growth potential for GLP-1 therapies, There will be a requirement for significantly higher volumes and Biocons fermentation capability will give us a significant advantage. India leads with a CAGR of 8.4%, driven by a large diabetic population and increasing demand for effective treatments
In this comprehensive guide, we will explore exactly what you can expect when starting this medication, how to find relief, and proactive steps you can take to make your wellness journey as comfortable as possible
The Onmorlo GLP-1 patches represent one attempt at needle-free delivery